Eli Lilly and Company (NYSE: LLY), an Indianapolis, IN-based medicine company, acquired Morphic Holding, Inc. (NASDAQ: MORF), a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases.
The amount of the deal was not disclosed.
With the acquisition, Lilly will improve outcomes and expand options for people living with inflammatory bowel disease.
Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).
FinSMEs
19/08/2024